Meeting
2022 ASCO Genitourinary Cancers Symposium
Efficacy and safety of relugolix in black men with advanced prostate cancer: A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide.
Presenter
Daniel J. George, FASCO, MD
Duke Cancer Institute
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03085095
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 105)
DOI
10.1200/JCO.2022.40.6_suppl.105
Abstract #
105
Poster Bd #
F2
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
Efficacy and safety of relugolix in men with advanced prostate cancer based on baseline body mass index (BMI): A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide (LEU).
Speaker: Fred Saad, MD, FRCS
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix verus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase 3 HERO study.
Speaker: Neal D. Shore, MD, FACS
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
Testosterone recovery for relugolix versus leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study.
Speaker: Ronald F. Tutrone, MD, FACS
Videos & Slides
2020 ASCO Virtual Scientific Program
HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.
Speaker: Neal D. Shore, FACS, MD